Filing Details

Accession Number:
0001209191-10-045286
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-09-07 16:07:00
Reporting Period:
2010-09-02
Filing Date:
2010-09-07
Accepted Time:
2010-09-07 16:07:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1009356 Salix Pharmaceuticals Ltd SLXP Pharmaceutical Preparations (2834) 943267443
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1053880 F John Chappell 1700 Perimeter Park Drive
Morrisville NC 27560
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2010-09-02 4,000 $39.40 469,480 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 250,000 Indirect By GRAT
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Option to Buy Common Stock $17.63 2015-06-09 15,000 15,000 Direct
Common Stock Option to Buy Common Stock $18.87 2014-06-17 22,500 22,500 Direct
Common Stock Option to Buy Common Stock $7.60 2013-07-24 15,000 15,000 Direct
Common Stock Option to Buy Common Stock $4.07 2012-07-02 15,000 15,000 Direct
Common Stock Option to Buy Common Stock $4.92 2001-01-01 2010-12-31 22,500 22,500 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2015-06-09 15,000 15,000 Direct
2014-06-17 22,500 22,500 Direct
2013-07-24 15,000 15,000 Direct
2012-07-02 15,000 15,000 Direct
2010-12-31 22,500 22,500 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.36 and $39.44, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  2. These shares were previously reported as directly benefically owned but were contributed to a grantor retained annuity trust on October 30, 2007.
  3. Options are 100% vested.